Skip to content
Review

Computational Strategies for Investigating Phytochemicals in Drug-resistant Tuberculosis.

Oct 2026 · Recent Advances in Anti-Infective Drug Discovery · 0 citations
Medicine

TL;DR

Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB and offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications.

Abstract

INTRODUCTION Tuberculosis (TB) is a serious global health concern precipitated by the pathogen Mycobacterium tuberculosis. The manifestation of drug-resistant forms of tuberculosis, such as extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains, makes treatment more difficult.

Methods

Innovative methods are required to find novel therapies because traditional drug development procedures are expensive and time-consuming. So, computational phytochemistry, which utilizes computer-aided techniques to create and find novel medications from natural plant molecules, provides new opportunities for the discovery of antitubercular agents. (DR-TB). This review aims to critically evaluate the potential of computational phytochemistry in accelerating the discovery of phytochemical-based therapeutics against drug-resistant tuberculosis. Relevant literature was examined, focusing on computational approaches including molecular docking, virtual screening, quantitative structure- activity relationship (QSAR) analysis, molecular dynamics (MD) simulations, artificial intelligence- assisted screening, pharmacophore modeling, and ADMET prediction for identifying promising anti-TB phytochemicals targeting key Mycobacterium tuberculosis proteins.

Results

The reviewed studies revealed that several classes of phytochemicals, including flavonoids, alkaloids, terpenoids, and phenolic compounds, demonstrated strong binding affinities toward validated drug-resistant TB targets such as InhA, DprE1, KasA, PknB, and DNA gyrase. Studies employing integrated computational workflows combining molecular docking, molecular dynamics simulations, and ADMET analyses provided more reliable predictions than docking-only approaches, facilitating the identification and optimization of potential anti-TB lead compounds.

Discussion

Given the prevalence of DR-TB and the shortcomings of existing treatments, this strategy tackles the urgent need for novel treatments. By fusing the enormous diversity of plant chemicals with computational capacity, this research offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications.

Conclusion

Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB. These encouraging in silico findings must be translated into successful treatments for drug-resistant tuberculosis, which will require more in vitro antimycobacterial screening, target-based biochemical assays, pharmacokinetic and toxicity studies, in vivo efficacy evaluation in tuberculosis models, and ultimately clinical validation. Future studies should also integrate artificial intelligence- driven drug discovery and multi-target screening approaches to improve hit identification and lead optimization for combating drug-resistant tuberculosis.

View source

Similar papers

Review Open access Oct 2026

Computational drug screening for drug-resistant tuberculosis: advances, challenges, and future perspectives

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health challenge, further exacerbated by the rapid emergence of drug-resistant strains. Despite continuous efforts, the discovery of novel anti-TB agents has lagged behind the evolution of resistance, largely due to the limitations of conve...

Shan-Shan Hu, Xiao-Yu Li, Z. Batool et al. · 0 citations
Review Sep 2026

Computational small molecule drug discovery for multidrug-resistant tuberculosis: emerging targets and recent medicinal chemistry advances.

Tuberculosis (TB) remains a major global health challenge, further intensified by the emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, which compromise the effectiveness of existing therapeutic regimens. Despite significant progress in TB chemotherapy, prolonged treatment durat...

Pardeep Kumar, Ankita Devi, Sridevi Bhima et al. · 2 citations
Open access Sep 2026

Integrated Computational Strategies for identifying Potential Drug Candidates against Spinal Tuberculosis

Drug resistance against various diseases including tuberculosis (TB) is an unfortunate reality of humankind. Total drug resistance (TDR) against TB has been a major cause of increasing cases throughout the world. Moreover, finding a new drug is more challenging against such a disease. Herein, we have selected a drug ta...

S. Sharma, Amresh Prakash · 0 citations
Open access Oct 2026

Pathway-Based Analysis of Metabolic Enzymes as Drug Targets

The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.

D. Bhat, Bhupender Singh · 0 citations
Open access Sep 2026

In silico assessment of natural compounds against mycobacterium tuberculosis Rv1509 protein

Tuberculosis (TB) remains a leading cause of mortality globally, driven by the infectious pathogen, Mycobacterium tuberculosis (M.tb). A novel DNA methyltransferase (DNA MTase), encoded by the Rv1509 gene and involved in TB pathogenesis, has been identified as a promising therapeutic target of anti-TB drugs. The presen...

Haleema Fayaz, Waseem Ali, Gauri Shrivastava et al. · 0 citations
Review Sep 2026

Computational and Natural Product Strategies in Anti-leishmanial Drug Discovery.

A critical synthesis of data from both natural product bioactivity catalogues and methodology reviews is provided to evaluate the translational feasibility of selected natural products with respect to their selectivity index and tiered classification for in vivo validation purposes.

Debajyoti Roy, Pitam Ghosh, Maitrayee Ghosh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.